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Abstract
Background: The clinical impact of PlA2 polymorphism has been investigated in several diseases, but the
definition of its specific role on thrombotic cardiovascular complications has been challenging. We aimed to
explore the effect of PlA2 polymorphism on outcome in patients with atherosclerosis.
Methods: We studied 400 consecutive patients with coronary artery disease (CAD) undergoing percutaneous
coronary intervention. A replication study was conducted in 74 hypertensive patients with cerebrovascular events
while a group of 100 healthy subjects was included as control population. PlA genotype was determined by PCR-
RFLP on genomic DNA from peripheral blood cells. Major adverse cardiac events (MACE), were considered as end
points, and recorded at a mean follow up of 24 ± 4.3 months.
Results: The frequencies of PlA2 polymorphism was similar between groups and genotype distribution was in
Hardy-Weinberg equilibrium. In patients with CAD, the presence of PlA2 allele was associated with higher
incidence of cardiac death (13.1% vs. 1.5%, p = 0.0001), myocardial infarction (10.7% vs. 2.6%, p = 0.004) and needs
of new revascularization (34.8% vs. 17.7%, p = 0.010). Accordingly, the Kaplan-Meier analysis for event free survival
in patients harboring the PlA2 allele showed worse long-term outcome for these patients (p = 0.015). Cox
regression analysis identified the presence of PlA2 as an independent predictor of cardiac death (OR: 9.594, 95% CI:
2.6 to 35.3, p = 0.002) and overall MACE (OR: 1.829, 95% CI: 1.054 to 3.176, p = 0.032). In the replication study, the
PlA2 polymorphism increased the risk of stroke (OR: 4.1, 95% CI: 1.63-12.4, p = 0.02) over TIA and was identified as
an independent risk factor for stroke (B:-1.39; Wald: 7.15; p = 0.001).
Conclusions: Our study demonstrates that in patients with severe atherosclerosis the presence of PlA2 allele is
associated with thrombotic cardiovascular complications.
Background
Atherosclerosis manifesting as myocardial infarction,
angina pectoris, cerebral ischemia and peripheral artery
disease is a multifactorial disease with the environment
and genetics contributing to its pathogenesis. During
the last decade several genes involved in the athero-
sclerotic process and their polymorphisms have been
suspected to increase the thrombotic predisposition and
to influence the risk for acute coronary syndromes.
Among these genes, polymorphisms of those involved in
platelet function have been extensively studied. Indeed,
platelets play a pivotal role in atherothrombosis [1] and
their function is strongly related to the interactions of
the glycoprotein IIb/IIIa receptor (GP IIb/IIIa) and the
von Willebrand factor, as well as fibrinogen, leading to
platelets aggregation [2-4]. GP IIIa is a high poly-
morphic protein with platelet antigen 1 (PlA1) and 2
(PlA2) as the most common allelic isoforms [5]. In the
PlA2 allele, cytosine is substituted for thymidine in exon
2, which is phenotypically translated in the substitution
of proline for leucine at position 33 of the mature GP
IIIa [6]. A previous in vitro study demonstrates that the
PlA2 variant enhances the binding of the GPIIb/IIIa
receptor to fibrinogen and therefore increases the plate-
let aggregation induced by agonists [7]. The clinical
impact of PlA2 polymorphism has been investigated in
several diseases, in which thrombus formation is a key
pathogenetic factor, but the definition of the specific
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and cerebrovascular complications has been challenging.
Weiss et al. [8] observed a strong association between
the PlA2 polymorphism of the GP IIIa gene and acute
coronary thrombosis, and this association was strongest
in patients who had had coronary events before the age
of 60 years, suggesting this polymorphism as an inher-
ited risk factor for coronary thrombosis. These findings
were further expanded on peripheral artery disease by
Mikkelson [9] who reported an association between
PlA2 variant and the progression of atherosclerosis in
the abdominal aorta. Similarly, in the Copenhagen City
Heart Study, a prospective study with 9,149 subjects,
there was a three-fold and four-fold risk of ischemic car-
diovascular disease and MI in men <40 years homozy-
gous for PlA2 polymorphism [10]. On the other hand,
several studies failed to confirm this association; indeed
a metanalysis of 23 of such negative studies, showed the
lack of association between the PlA2 allele and the risk
of myocardial infarction and this negative result per-
sisted even after subgroup analyses [11]. Therefore, up
to date, available data are hugely uncertain and still
debated. Several issues common to epidemiologic risk
factor studies can be accountable for the difficulty
encountered in reproducing the results of genetic asso-
ciation studies. Among these limitations there is inaccu-
rate phenotyping [12]. In particular, atherosclerotic
disease may present with different clinical manifesta-
tions. It is therefore pivotal to accurately select the clini-
cal phenotype that can be affected by the genetic
variability. To address this issue, and therefore gain
more inside on the role of PlA2 polymorphism on
atherothrombotic disease, we performed a prospective
study in a cohort of patients selected for angiography
documented severe coronary artery disease (CAD),
which needed percutaneous coronary intervention (PCI).
Moreover, to assess the role of this polymorphism on
cerebrovascular disease, a replication study was per-
formed in an independent population of hypertensive
subjects, screened for large vessel atherosclerotic disease,
and previous ischemic cerebrovascular events, namely
stroke or transient ischemic attack (TIA). Finally, a
group of 100 healthy subjects was included as control
population of our study.
Methods
Patients
To assess the role of PlA2 polymorphism on cardiovas-
cular disease we analyzed the incidence of this gene var-
iant in a total of 574 unrelated individuals. A first group
was constituted by 400 consecutive patients (mean age
60.5 ± 10, 83% male) undergoing elective or urgent PCI
for CAD documented by a positive stress test or by Tl
single photon emission computed tomography. To
perform a replication analysis we selected an indepen-
dent population of patients with cerebrovascular disease.
Therefore, a population of 74 unrelated patients (mean
age 61.58 ± 2, 63% male) with cerebrovascular events
was examinated, recruited from those admitted to the
Hypertension Diagnosis and Care Outpatient Clinic of
“Federico II” University of Naples and participating in
the ‘Campania Salute Project’ [13]. Finally, to identify
normal distribution of the PlA genotype, we enrolled a
control population of 100 gender- and age-matched
healthy unrelated individuals (60 ± 10 years, 83% male),
recruited from blood donors of our blood bank. Con-
trols were free from heart disease, medication use, and
cardiovascular risk factors, except for smoking habits.
To help to diminish the likelihood of bias and reduce
population stratification case and controls individuals
were drawn from the same geographic region (Campa-
nia, Southern Italy) and matched for age, sex and race.
All clinical data and biochemical features of enrolled
patients were stored in a computerized database. A writ-
ten informed consent was obtained from all patients
according to the Ethics Committee of the “Federico II”
University of Naples School of Medicine. The Ethic
Committee regulations of our Institution approved the
study protocol.
Percutaneous coronary intervention
PCI was performed according to the American Heart
Association/American College of Cardiology guidelines
[14]. Antegrade perfusion was graded by Thrombolysis
In Myocardial Infarction (TIMI) criteria [15]. Angio-
graphic lesion morphology was classified according to
American Heart Association/American College of Cardi-
ology classification [16]. Stenoses >50% were considered
significant. Bare-metal stents (BMS) were used in the
80% of patients, while drug-eluting stent (DES) in the
remaining 20%. Glycoprotein IIb/IIIa inhibitors were
used in 30% of patients. After the procedures, all
patients were on dual antiplatelet therapy with aspirin
and clopidogrel for at least 30 days after BMS implanta-
tion and for 12 months after DES. Other cardioactive
drugs for long-term medical treatment were left to the
discretion of the attending cardiologists.
Outcome evaluation
In the evaluation of long-term clinical outcome, major
adverse cardiac events (MACE) were considered as end
points, including cardiac death, acute myocardial infarc-
tion (AMI), and needs of any new myocardial revascu-
larization (considering re-PCI or coronary artery by-pass
graft). All deaths were considered as cardiac, unless it
was unequivocally proven non-cardiac. AMI was defined
as recurrent chest pain with ST-segment or T-wave
changes and recurrent elevation of cardiac enzyme
Galasso et al. BMC Cardiovascular Disorders 2010, 10:41
http://www.biomedcentral.com/1471-2261/10/41
Page 2 of 7levels. The follow-up was based on a direct systematic
review of all patients’ clinical files for a mean study per-
iod of 24 ± 4.3 months, contacting relatives or a
patient’s physician when necessary. Follow-up was com-
pleted in all patients and data stored in a computerized
database. A second population was identified among the
hypertensive cohort of patients afferent to the ‘Campa-
nia Salute Project’ [13]. We selected 74 patients affected
by cerebrovascular events, either TIA or stroke. In parti-
cular, the diagnosis of TIA or stroke was confirmed by
neurological evaluation according to current standards
for care [17]. This included patient personal and family
history, physical examination, computed tomography or
magnetic resonance imaging, and laboratory testing. The
diagnosis of stroke was based on WHO criteria, con-
firmed by TC or MR, when needed. The cause of stroke
was identified in large-vessel disease, according to the
clinical features and results of the diagnostic workup,
based on TOAST pathophysiological classification [18].
TIA was defined as an episode of focal neurological
symptoms with abrupt onset and rapid resolution lasting
<24 hours that is due to altered circulation to a loca-
lized portion of the brain [19].
GpIIIa genotyping
Using a commercially available kit (Midiprep DNA, Qia-
gen, Valencia, California), genomic deoxyribonucleic
acid (DNA) was isolated from 2 ml of the peripheral
blood samples. PlA2 polymorphism was studied using
combined polymerase chain reaction (PCR) and restric-
tion fragment length polymorphism technique (RFLP)
on PCR amplified products using PCR conditions and
primers on a Thermocycler (MJ Research, St. Bruno,
Canada) and DNA polymerase (TAQ, Qiagen) as pre-
viously reported [20,21].
Statistical Analysis
Continuous variables are presented as mean ± SD and
categorical variables as absolute number and percentage
value. Differences between groups were assessed using
univariate analysis of variance for continuous variables,
with a Bonferroni post-hoc test for evaluation of multi-
ple comparisons. Categorical variables were analyzed by
chi-square test, and odds ratio (OR) with 95% confi-
dence intervals (CIs) or by the Fisher exact test when
the expected values in any of the cells of the test, given
the frequencies and the overall sample size, was below
10; p value <0.05 was considered significant. Difference
in event-free survival between groups were evaluated by
the Kaplan-Meier method, comparisons were made
using log-rank test. A Cox regression analysis was con-
ducted for the PlA2 polymorphism considering age, car-
diovascular risk factors, medication use, left ventricular
ejection fraction, angiographic characteristics, and
interaction of the PlA2 polymorphism in both the study
populations. The software used was SPSS 16 (SPSS Inc.,
Chicago, Illinois).
Results
Frequencies of PlA2 polymorphism in study population
As reported in Table 1, the frequencies of PlA2 poly-
morphism was similar between study and control group.
The genotype distribution was in Hardy-Weinberg equi-
librium. The allele frequency for PlA1 and PlA2 was,
respectively, 84% and 16% in patients with CAD, 82.3%
and 17.7% in hypertensive subjects with cerebrovascular
events, and 84.5% and 15.5% in the control healthy
group.
Clinical and angiographic characteristics in patients with
coronary artery disease
Accordingly to the allelic distribution of the PlA2 allele
we divided patients with CAD into 2 groups: group 1
(300 patients, PlA1/PlA1 genotype; 90% male, mean age
60 ± 10 years) and group 2 (100 patients, PlA1/PlA2
and PlA2/PlA2 genotypes; 81% male, mean age 62.1 ±
8.6 years). As reported in tables, no differences were
noted between the two groups regarding baseline clini-
cal (table 2) and angiographic (table 3) features.
Table 1 Genotype distribution of PlA2 polymorphism in
study populations
Genotype CAD
patients
Hypertensive
patients
Control
population
P
PlA1/A1 70.4 67.8 72 0.79
PlA1/A2 27 29.1 25 0.91
PlA2/A2 2.6 3.1 3 0.81
CAD: Coronary artery disease
Table 2 Clinical characteristics of CAD patients
Variable PlA1
(n = 300)
PlA2
(n = 100)
p
Value
Age 60 ± 10 62.1 ± 8.6 0.72
Male sex (%) 90 81 0.03
Hypertension (%) 56 57 0.82
Diabetes (%) 29.3 19.4 0.11
Smoking (%) 58.6 53.8 0.45
Dyslipidemia (%) 55.2 53.8 0.81
Obesity (%) 9.5 7.7 0.89
Family history of CAD (%) 38.2 33.4 0.37
Previous AMI (%) 10.9 15.4 0.35
Previous PCI (%) 10.9 15.4 0.35
Previous CABG (%) 9.1 3.8 0.15
LVEF prior to PCI, mean ± SD 47 ± 10 51 ± 8 0.06
PCI: Percutaneous coronary intervention
LVEF: Left ventricular ejection fraction
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There were no differences between groups regarding
medication use at the time of PCI and during follow-up
time. In particular, at follow-up time both groups were
similarly treated, using dual antiplatelet therapy (99% vs.
98% group 2, p = NS), calcium antagonist (19% vs. 18%
group 2, p = NS), beta-blockers (45% vs. 47% group 2,
p = NS), angiotensin-converting enzyme inhibitors
(36% vs. 34% group 2, p = NS), and statins (42% vs.
40% group 2, p = NS).
Long-term follow-up
There were no significant differences between groups
regarding MACE incidence during hospitalization.
Interestingly, at long-term follow-up, the rates of
MACE were significantly higher in PlA2 group com-
pared to PlA1 (43.5% vs 25.8%, p 0.018). In particular,
patients with PlA2 allele showed a significant increased
rate of cardiac death (14.6% vs 5.3%, p = 0.025), AMI
(12% vs 4.5%, p = 0.043) and new myocardial revascu-
larization (34.8% vs 17.7%, p = 0.010). Accordingly, the
Kaplan-Meier analysis for event free survival in
patients harboring the PlA2 allele (Figure 1) showed
worse long-term outcome for these patients (p =
0.015). Cox regression analysis identified the presence
of PlA2 allele as an independent predictor for cardiac
death (OR: 9.594, 95% CI: 2.6 to 35.3, p = 0.002) and
overall MACE (OR: 1.973, 95% CI: 1.039 to 3.747, p =
0.036). There were no interactions noted for this rela-
tionship when considering age, sex, risk factors for
CAD, multivessel disease, previous myocardial revascu-
larization, number of treated lesions, and basal left
ventricular ejection fraction.
Effect of PlA2 polymorphism on cerebrovascular events in
hypertensive patients
To analyze in a different population the impact of this
polymorphism on atherothrombotic events we analyzed
the impact of PlA2 in hypertensive patients with history
of cerebrovascular events according to the level of cere-
bral damage (TIA or stroke). The characteristics of
these patients are depicted in table 4. Both the TIA and
stroke groups presented with an elevated cardiovascular
risk due to the presence of many risk factors which dis-
tribution did not differ between the two groups. Inter-
estingly, PlA2 allele was significantly more represented
among patients with stroke than patients with TIA
(stroke:46.4%; TIA:17.4%; p = 0.01). This polymorphism
indeed increased the risk of stroke in this high risk
population (OR: 4.1, 95% CI: 1.63-12.4, p = 0.02) over
TIA. Finally, a multiple regression analysis corrected by
common risk factors for cerebrovascular events, showed
that PlA2 allele as an independent risk factor for stroke
(B:-1.39; Wald: 7.15; p = 0.001).
Discussion
The main finding of this study is the relationship
between the PlA2 gene variant and the incidence of
major adverse cardiovascular events in patients harbour-
ing the PlA2 gene polymorphism. Indeed, in patients
with CAD undergoing PCI we found that the presence of
PlA2 allele associated with a significantly worse prognosis
with a higher incidence of cardiac death, AMI, and new
myocardial revascularization. Moreover, in an indepen-
dent population of hypertensive patients with large vessel
atherosclerosis and previous cerebrovascular events,
patients harbouring the PlA2 gene polymorphism
Table 3 Angiographic characteristics of CAD patients
Variable PlA1
(n = 300)
PlA2
(n = 100)
p Value
Coronary artery disease (%)
LAD 61.9 50 0.27
Cx 33.6 29 0.37
Dx 45 50 0.30
Multivessel Disease (%) 28 30 0.49
Lesion type, B2/C (%) 78 85 0.55
BMS (%) 74 66 0.56
DES (%) 26 34 0.57
TIMI 3 post PCI (%) 97.5 98 0.89
cTFC post (mean ± SD) 15.10 ± 6 14.25 ± 8 0.76
Lesion length (mm) 15.54 ± 6.59 16.48 ± 8.74 0.13
Preprocedural stenosis (%) 86.55 ± 10.19 85.05 ± 11.48 0.11
Stent/patient (n) 1.08 ± 0.32 1.07 ± 0.26 0.74
BMS: Bare metal stent, Cx: Left circumflex coronary artery, DES: Drug eluting
stent, Dx: Right coronary artery, LAD: Left anterior descending coronary artery.
Figure 1 Observed event free survival curve at follow up:
Patients with coronary artery disease harbouring the PlA2 allele of
the GP III a gene (group 2) had a higher incidence of MACE with
reduced event free follow up time as indicated by the Kaplan Meier
analysis.
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over TIA. Taken together these data suggest an effect for
the PlA2 gene polymorphism in the development of
more severe thrombotic complications in high risk
patients.
Since the original report from Weiss et al. [8] indicat-
ing PlA2 polymorphism as a risk factor for myocardial
infarction or unstable angina, several studies have investi-
gated this polymorphism in the effort to discover a novel
thrombogenic risk factor but to date results have been
inconclusive and often controversial [8,11,22]. The incon-
sistence of findings in literature can be mostly attributed
to differences in the design as well as to the choice of the
control group and the endpoint of the studies. Moreover,
studies differ in the variation of environmental factors
and ethnicity, present biases in the selection of patients
and controls and often aim to different clinical endpoints.
Since atherosclerosis is a multifactorial disease, it would
be too simplistic to explain interindividual variations
based on genetic inheritance alone. Indeed several chal-
lenges exist in identifying the genetic determinants of
such a complex disease including genetic heterogeneity,
gene-gene and gene-environment interactions [12].
Furthermore, interaction of multiple genes that are in
linkage disequilibrium and simultaneous studies of sev-
eral genes may reveal associations that at present seem to
be weak. Nevertheless, such approaches are costly, and
impose the use of large populations and heavy statistic
modeling in order to carefully peruse small impact of sin-
gle gene variants on multifactorial disease [12]. There is
still room for candidate gene association study that can
be performed in relatively small populations, that are
carefully characterized and selected for homogeneity
[12]. We also have recently underlined the need for accu-
rately selection of patients in association studies in order
to identify the populations in which single gene poly-
morphisms may be more determinant in complex pheno-
types such as atherosclerosis [20,21]. Therefore, since
platelets play a major role in the development of
atherosclerotic thrombosis and acute ischemic events, we
investigated the role of the PlA2 gene polymorphism in
higher risk populations such as patients with severe CAD
requiring mechanical revascularization and hypertensive
patients with previous cerebrovascular events. Interest-
ingly, in the CAD population, we observed that the pre-
sence of PlA2 patients was associated with a 3 times
higher risk of death or 2.8 increased risk of AMI. Note-
worthy, patients harbouring the PlA2 allele presented an
higher risk of needing new revascularization at follow up
with 50% of patients undergoing new PCI for the occur-
rence of a new myocardial infarction. This is consistent
with data by Kastrati et al [23] reporting a higher risk of
restenosis after coronary stent placement in these
patients. Moreover, in an independent population of
hypertensive patients with cerebrovascular events, the
presence of the PlA2 allele was associated with a 4.1
higher risk to develop stroke rather than TIA. Thus,
these data suggest that, in a high risk clinical scenario
represented by patients with a greater prevalence of
atherothrombotic risk factors, the presence of PlA2 is
associated with a more aggressive disease leading to an
higher incidence of major ischemic events and to an
unfavourable outcome. Our results only apparently differ
from the finding observed in a subgroup analysis of the
Physicians’ health study (PHS) [24] by Ridker et al. [25]
which prospectively studied the risk associated with the
PlA2 polymorphism for myocardial infarction, stroke or
venous thromboses and reported no associations between
PlA2 polymorphism and the relative risk to develop any
cardiac or cerebro-vascular event. Indeed, as already
remarked by previous studies [26,27], the PHS was con-
ducted in a very healthy population, with an event rate 4
times less than general population, and therefore with a
very low risk of cardiovascular events. Also, our analysis
focused on the outcome and the incidence of MACE in
patients that already had a clinical manifestation of the
disease, while the PHS aimed to the occurrence of the
first event.
Table 4 Characteristics of hypertensive patients
Variable Hypertensives with TIA (n = 46) Hypertensives with stroke (n = 28) P value
Age (years) 62.06 ± 1.63 61.1 ± 2.60 0.77
Male sex (%) 54.3 71.4 0.15
Diabetes (%) 9.7 10.6 0.88
Smoking (%) 55.3 58.1 0.75
Dyslipidemia (%) 51.1 51.6 0.95
SBP (mmHg) 150.08 ± 3.23 147.5 ± 2.88 0.42
DBP (mmHg) 87.94 ± 1.78 88.83 ± 2.16 0.97
LVMI (g/m
2) 127.09 ± 3.64 127.82 ± 2.68 0.98
DBP: Diastolic blood pressure
LVMI: Left Ventricle Mass Index
SBP: Systolic blood pressure
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prospective but observational study. Moreover, since this
is an association study, we cannot rule out the presence
of a possible linkage disequilibrium with other neighbor-
ing genes that might explain the significant association
with atherosclerotic phenotype or adverse prognosis.
The study was conducted in patients with severe CAD
undergoing PCI while the replication study was per-
formed in hypertensive patients with previous cerebro-
vascular events; therefore, our findings need to be
confirmed in further larger patient populations. Never-
theless, recent studies [20,21] underlines the need for
selection of patients in association studies in order to
identify the populations in which single gene poly-
morphisms may be more determinant in complex phe-
notypes such as CAD.
Conclusions and clinical implications
Our study suggests that the PlA2 polymorphism is asso-
ciated with a more aggressive atherothrombotic disease
and adversely affects the prognosis in these high risk
patients. Indeed, in patients with severe CAD under-
going PCI the presence of PlA2 allele is associated with
increased risk of death, myocardial infarction and new
myocardial revascularization. Moreover, high risk hyper-
tension patients harbouring the PlA2 allele show an
increased risk to develop severe cerebral damage. There-
fore considering the atherothrombotic disease, the PlA2
genotype could be useful to physicians in targeting
antithrombotic strategies and therapeutic options. Since
atherosclerosis is a multifactorial disease, future studies
on interactions between environmental factors, common
cardiovascular risk factors and platelet associated genetic
determinants are warranted.
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